The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Parkinson Disease

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Parkinson Disease


Psychiatry related information on Parkinson Disease


High impact information on Parkinson Disease


Chemical compound and disease context of Parkinson Disease


Biological context of Parkinson Disease


Anatomical context of Parkinson Disease


Gene context of Parkinson Disease


Analytical, diagnostic and therapeutic context of Parkinson Disease


  1. Treatment of Parkinson's disease with aporphines. Possible role of growth hormone. Cotzias, G.C., Papavasiliou, P.S., Tolosa, E.S., Mendez, J.S., Bell-Midura, M. N. Engl. J. Med. (1976) [Pubmed]
  2. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Zhou, B., Westaway, S.K., Levinson, B., Johnson, M.A., Gitschier, J., Hayflick, S.J. Nat. Genet. (2001) [Pubmed]
  3. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. Sternberg, E.M., Van Woert, M.H., Young, S.N., Magnussen, I., Baker, H., Gauthier, S., Osterland, C.K. N. Engl. J. Med. (1980) [Pubmed]
  4. Letter: Ammonia and L-dopa: Parkinson's disease and hepatic encephalopathy. Zieve, F.J. N. Engl. J. Med. (1975) [Pubmed]
  5. Identification of genes that modify ataxin-1-induced neurodegeneration. Fernandez-Funez, P., Nino-Rosales, M.L., de Gouyon, B., She, W.C., Luchak, J.M., Martinez, P., Turiegano, E., Benito, J., Capovilla, M., Skinner, P.J., McCall, A., Canal, I., Orr, H.T., Zoghbi, H.Y., Botas, J. Nature (2000) [Pubmed]
  6. Homozygosity mapping of Hallervorden-Spatz syndrome to chromosome 20p12.3-p13. Taylor, T.D., Litt, M., Kramer, P., Pandolfo, M., Angelini, L., Nardocci, N., Davis, S., Pineda, M., Hattori, H., Flett, P.J., Cilio, M.R., Bertini, E., Hayflick, S.J. Nat. Genet. (1996) [Pubmed]
  7. Gene-expression profile of the ageing brain in mice. Lee, C.K., Weindruch, R., Prolla, T.A. Nat. Genet. (2000) [Pubmed]
  8. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Guillin, O., Diaz, J., Carroll, P., Griffon, N., Schwartz, J.C., Sokoloff, P. Nature (2001) [Pubmed]
  9. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Van Tol, H.H., Bunzow, J.R., Guan, H.C., Sunahara, R.K., Seeman, P., Niznik, H.B., Civelli, O. Nature (1991) [Pubmed]
  10. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients. Meco, G., Alessandria, A., Bonifati, V., Giustini, P. Lancet (1994) [Pubmed]
  11. Identification of intrinsic determinants of midbrain dopamine neurons. Andersson, E., Tryggvason, U., Deng, Q., Friling, S., Alekseenko, Z., Robert, B., Perlmann, T., Ericson, J. Cell (2006) [Pubmed]
  12. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Chandra, S., Gallardo, G., Fernández-Chacón, R., Schlüter, O.M., Südhof, T.C. Cell (2005) [Pubmed]
  13. Mutations in NR4A2 associated with familial Parkinson disease. Le, W.D., Xu, P., Jankovic, J., Jiang, H., Appel, S.H., Smith, R.G., Vassilatis, D.K. Nat. Genet. (2003) [Pubmed]
  14. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Liu, Y., Fallon, L., Lashuel, H.A., Liu, Z., Lansbury, P.T. Cell (2002) [Pubmed]
  15. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Shimura, H., Hattori, N., Kubo, S., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., Suzuki, T. Nat. Genet. (2000) [Pubmed]
  16. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. Nutt, J.G., Woodward, W.R., Hammerstad, J.P., Carter, J.H., Anderson, J.L. N. Engl. J. Med. (1984) [Pubmed]
  17. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. Freed, C.R., Greene, P.E., Breeze, R.E., Tsai, W.Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J.Q., Eidelberg, D., Fahn, S. N. Engl. J. Med. (2001) [Pubmed]
  18. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Burns, R.S., LeWitt, P.A., Ebert, M.H., Pakkenberg, H., Kopin, I.J. N. Engl. J. Med. (1985) [Pubmed]
  19. Association between early-onset Parkinson's disease and mutations in the parkin gene. Lücking, C.B., Dürr, A., Bonifati, V., Vaughan, J., De Michele, G., Gasser, T., Harhangi, B.S., Meco, G., Denèfle, P., Wood, N.W., Agid, Y., Brice, A. N. Engl. J. Med. (2000) [Pubmed]
  20. Treatment of parkinson's disease with bromocriptine. Lieberman, A., Kupersmith, M., Estey, E., Goldstein, M. N. Engl. J. Med. (1976) [Pubmed]
  21. Medication-related impulse control and repetitive behaviors in Parkinson's disease. Voon, V., Potenza, M.N., Thomsen, T. Curr. Opin. Neurol. (2007) [Pubmed]
  22. Plasma urate and risk of Parkinson's disease. Weisskopf, M.G., O'Reilly, E., Chen, H., Schwarzschild, M.A., Ascherio, A. Am. J. Epidemiol. (2007) [Pubmed]
  23. Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease. Brownell, A.L., Jenkins, B.G., Elmaleh, D.R., Deacon, T.W., Spealman, R.D., Isacson, O. Nat. Med. (1998) [Pubmed]
  24. Basic fibroblast growth factor increases dopaminergic graft survival and function in a rat model of Parkinson's disease. Takayama, H., Ray, J., Raymon, H.K., Baird, A., Hogg, J., Fisher, L.J., Gage, F.H. Nat. Med. (1995) [Pubmed]
  25. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Gerfen, C.R., Engber, T.M., Mahan, L.C., Susel, Z., Chase, T.N., Monsma, F.J., Sibley, D.R. Science (1990) [Pubmed]
  26. Impaired locomotion and dopamine signaling in retinoid receptor mutant mice. Krezel, W., Ghyselinck, N., Samad, T.A., Dupé, V., Kastner, P., Borrelli, E., Chambon, P. Science (1998) [Pubmed]
  27. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. Kish, S.J., Shannak, K., Hornykiewicz, O. N. Engl. J. Med. (1988) [Pubmed]
  28. ADDENDUM: Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Gill, S.S., Patel, N.K., Hotton, G.R., O'sullivan, K., McCarter, R., Bunnage, M., Brooks, D.J., Svendsen, C.N., Heywood, P. Nat. Med. (2006) [Pubmed]
  29. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Conway, K.A., Harper, J.D., Lansbury, P.T. Nat. Med. (1998) [Pubmed]
  30. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Kim, J.H., Auerbach, J.M., Rodríguez-Gómez, J.A., Velasco, I., Gavin, D., Lumelsky, N., Lee, S.H., Nguyen, J., Sánchez-Pernaute, R., Bankiewicz, K., McKay, R. Nature (2002) [Pubmed]
  31. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Dunnett, S.B., Björklund, A. Nature (1999) [Pubmed]
  32. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Chung, K.K., Zhang, Y., Lim, K.L., Tanaka, Y., Huang, H., Gao, J., Ross, C.A., Dawson, V.L., Dawson, T.M. Nat. Med. (2001) [Pubmed]
  33. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Gill, S.S., Patel, N.K., Hotton, G.R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D.J., Svendsen, C.N., Heywood, P. Nat. Med. (2003) [Pubmed]
  34. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Suh, Y.H., Checler, F. Pharmacol. Rev. (2002) [Pubmed]
  35. Defective Fas expression exacerbates neurotoxicity in a model of Parkinson's disease. Landau, A.M., Luk, K.C., Jones, M.L., Siegrist-Johnstone, R., Young, Y.K., Kouassi, E., Rymar, V.V., Dagher, A., Sadikot, A.F., Desbarats, J. J. Exp. Med. (2005) [Pubmed]
  36. Parkin: a multipurpose neuroprotective agent? Feany, M.B., Pallanck, L.J. Neuron (2003) [Pubmed]
  37. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Cookson, M.R. Nat. Rev. Neurosci. (2010) [Pubmed]
  38. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. Rascol, O., Brooks, D.J., Korczyn, A.D., De Deyn, P.P., Clarke, C.E., Lang, A.E. N. Engl. J. Med. (2000) [Pubmed]
  39. Effects of tyrosine administration on serum biopterin in normal controls and patients with Parkinson's disease. Yamaguchi, T., Nagatsu, T., Sugimoto, T., Matsuura, S., Kondo, T., Iizuka, R., Narabayashi, H. Science (1983) [Pubmed]
  40. Basal ganglia and movement disorders: an update. Chesselet, M.F., Delfs, J.M. Trends Neurosci. (1996) [Pubmed]
WikiGenes - Universities